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In the course of active, progressive chronic lymphocytic leukemia (CLL), patients have infiltration of peripheral lymphoid tissue and bone marrow with the malignant, monoclonal B cells coexpressing CD5, CD19 and CD23. This is manifest as lymphocytosis, progressive lymphadenopathy and hepatosplenomegaly, and can be associated with progressive neutropenia, anemia and thrombocytopenia. Up to 25% of patients with CLL, including those with stable disease, develop secondary autoimmune disorders, which can confound cytopenias, complicate the course of their CLL, compromise their quality of life, and in some cases can be fatal. 1 The most common among autoimmune disorders in CLL are autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP) and pure red cell aplasia (PRCA). 2 Indeed, CLL is one of the most common secondary causes of ITP. 3 Historically, it was hypothesized that rapid splenic and hepatic clearance of autoantibody-loaded platelets from the circulation was the primary mechanism for decreased platelet count in ITP. 4 However, recent studies showed that impaired platelet production also contributes to the pathogenesis of ITP. 5 Consistent with these findings, two second-line thrombopoietin receptor (TPO-R) agonists, romiplostim (Nplate, Amgen, Thousand Oaks, CA, USA) and eltrombopag (Promacta, GlaxoSmithKline, Research Triangle Park, NC USA), 6 showed remarkable efficacy in patients with primary ITP. 7, 8 As these trials excluded patients with secondary ITP, the activity of these new drugs in CLL-associated ITP has not been reported. Thus, we present two patients with CLL and secondary ITP who responded to eltrombopag. We identified two patients followed at MD Anderson Cancer Center with CLL and ITP who received the TPO-R agonist eltrombopag (Table 1) . A third patient was identified who received eltrombopag, but did not respond.
Patient 1 was a 74-year-old female diagnosed with Rai stage 0 CLL in December 1995. She received multiple previous treatment regimens for her CLL, and then developed severe thrombocytopenia in May 2009, 5 months after her third course of combined oxaliplatin, fludarabine, cytarabine and rituximab (OFAR). She was noted to have 17p del in 72% of leukemia cells by fluorescence in situ hybridization (FISH), which is a high-risk feature in CLL. Her platelet count dropped from 89 Â 10 3 to 1 Â 10 3 /ml and she received infrequent platelet transfusions for minor bleeding without improvement in platelet counts.
Patient 2 was a 49-year-old male who presented in October 2004 with thrombocytopenia and was concurrently diagnosed with CLL and ITP. He was initially treated with prednisone for his ITP, then with one course of fludarabine with cyclophosphamide and then with single-agent rituximab. Following this, in December 2004, his CLL was in partial remission with residual CLL in his marrow, and his platelets were stable at approximately 100 Â 10 3 /ml. FISH analysis of leukemia cells showed 11q deletion in 16.5% of cells. Subsequently, despite stable CLL by other parameters, over several months his platelet count dropped to 30 Â 10 3 /ml when treatment for ITP was considered. Abbreviations: CLL, chronic lymphocytic leukemia; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide and rituximab; FISH, fluorescence in situ hybridization; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGB, hemoglobin; lymphs, lymphocytes; ITP, immune thrombocytopenic purpura; OFAR, oxaliplatin, fludarabine, cytarabine, and rituximab; PLT, platelet; Tx, treatment; WBD, white blood count. /ml (transfusion independent). Patient 2 has a rapid response in platelet count, reaching high enough count to perform laparoscopic splenectomy. The platelet count of patient 2 dropped after splenectomy and off eltrombopag; he has not been retreated. ANC, ALC and HGB for patients 1 (b) and 2 (c) are shown from the start of eltrombopag. There was an overall reduction in ALC and HGB for patient 1.
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Neither patient had splenomegaly or rapid change in CLL tumor burden before onset of thrombocytopenia, making ITP the most reasonable diagnosis for both. Neither was evaluated for antiplatelet antibodies. Initially, both patients were treated with prednisone (1 mg/kg) and re-evaluated after 1 week. Patient 1 continued to have a low platelet count (PLT: 13 Â 10 3 /ml, transfused) after 4 weeks on prednisone and was started on eltrombopag 50 mg daily. Prednisone was tapered off over 1 week. From that time on, patient 1 has only been on eltrombopag and has not received anti-CLL treatment. Patient 2 did not respond to prednisone after 1 week and additionally received cyclosporine A (300 mg daily). After 5 months on cyclosporine A and prednisone with a platelet count of 23 Â 10 3 /ml, patient 2 received weekly standard-dose rituximab for 8 weeks and cyclosporine A and prednisone were tapered off over a month. He reached a platelet count of 167 Â 10 3 /ml 2 months after rituximab but then only 5 months later he lost his response, and he received four additional weekly doses of rituximab, and again had a normal platelet count. Rituximab ( Â 4) was repeated twice, each 6 months, before he agreed to splenectomy. To increase his platelet count from 36 Â 10 3 /ml to a safer level for laparoscopic splenectomy, patient 2 received eltrombopag 50 mg daily. Figure 1a shows the platelet count for patients 1 and 2 from start of eltrombopag treatment. Patient 1 has not received any antileukemia treatment and remains on eltrombopag 6 months after starting with her most recent blood count showing a platelet level of 77 Â 10 3 /ml. The platelet count of patient 2 rose from 36 Â 10 3 to 134 Â 10 3 /ml after 31 days on eltrombopag, before splenectomy. Eltrombopag was stopped shortly after splenectomy and his platelet count peaked at over 300 Â 10 3 /ml. The peak platelet count was likely secondary to the combined effects of eltrombopag and splenectomy. As shown in Figure 1a , stopping eltrombopag in patient 2 led to a decrease in platelet count to pretreatment level. This reduction after stopping eltrombopag was also observed in phase 2 and phase 3 studies of eltrombopag for primary ITP. Neither patient 1, who is still taking eltrombopag, nor patient 2 reported any eltrombopagrelated side effects. In addition, neither had any change in lymphadenopathy while on eltrombopag.
Both patients experienced changes in blood counts, including significant increase in platelet count while on eltrombopag (Figure 1 ). The presence of CLL cells in blood and bone marrow did not seem to have a negative effect on efficacy of eltrombopag; even patient 1, who had 470% of her bone marrow cellularity compromised of CLL cells at the beginning of her therapy, responded. In addition, for patient 1, there was a gradual decrease in hemoglobin (HGB) during treatment, but more remarkable was the drop in her absolute lymphocyte count (ALC) from 18 Â 10 3 /ml at the beginning of treatment to 5.5 Â 10 3 /ml over the first 6 months on eltrombopag. The absolute neutrophil count (ANC) for patient 1 remained stable. For patient 2, the change was owing to platelet response to eltrombopag; he had no significant change in his other counts, including ANC, ALC and HGB over the month of treatment.
Two points make these results with eltrombopag therapy in patients with CLL important. First, in a large number of cases of CLL-associated ITP, response to traditional treatment is transient and multiple treatment courses with different agents are needed to control ITP. Both patients responded relatively quickly to eltrombopag. One patient has had a durable response with continued treatment; the other was taken off treatment and has not been retreated. Second, currently available therapeutic option for secondary ITP is immunosuppression. In CLL, in which the disease itself impairs the immune system and infectious complications are common, additional suppression of the immune system can be detrimental. TPO-R agonists are non-immunosuppressive, can be administered over a long period of time, help to keep platelet counts continually above life-threatening levels and therefore preserve immune function. Indeed, these agents are intended for long-term administration; however, long-term safety data are lacking in both primary and secondary ITP.
These case reports show the activity of the TPO-R agonist eltrombopag in two patients with CLL-associated ITP who were refractory to standard treatment for ITP and therefore support further study of this and similar compounds in patients with secondary ITP.
